APAC Medicinal Chemistry for Drug Discovery Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF ASIA PACIFIC MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET 26
1.4 CURRENCY AND PRICING 28
1.5 LIMITATIONS 28
1.6 MARKETS COVERED 29
2 MARKET SEGMENTATION 32
2.1 MARKETS COVERED 32
2.2 GEOGRAPHICAL SCOPE 33
2.3 YEARS CONSIDERED FOR THE STUDY 34
2.4 DBMR TRIPOD DATA VALIDATION MODEL 35
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 38
2.6 MULTIVARIATE MODELLING 39
2.7 MARKET END USER COVERAGE GRID 40
2.8 PROCESS LIFELINE CURVE 41
2.9 DBMR MARKET POSITION GRID 42
2.10 VENDOR SHARE ANALYSIS 44
2.11 SECONDARY SOURCES 45
2.12 ASSUMPTIONS 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 50
4.1 PESTEL ANALYSIS 51
4.2 POTERS FIVE FORCES 52
5 ASIA PACIFIC MEDICINAL CHEMISTRY IN DRUG DISCOVERY MARKET: REGULATIONS 53
6 MARKET OVERVIEW 57
6.1 DRIVERS 59
6.1.1 INCREASE IN R&D FOR DISCOVERY AND DEVELOPMENT OF NOVEL DRUG MOLECULES 59
6.1.2 RISE IN CHRONIC DISEASES 59
6.1.3 INITIATIVES FOR RESEARCH ON RARE DISEASES AND ORPHAN DRUGS 60
6.1.4 GROWTH IN BIOLOGICS 61
6.1.5 COLLABORATIONS AMONG RESEARCHERS AND PHARMACEUTICAL INDUSTRIES 61

6.2 RESTRAINTS 62
6.2.1 RISE IN COST OF FORMULATED DRUG 62
6.2.2 TECHNICAL RISKS IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 62
6.2.3 BIOETHICAL ISSUES IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 62
6.3 OPPORTUNITIES 63
6.3.1 ADVANCEMENTS IN BIOCHEMICAL, TRANSLATIONAL, AND MOLECULAR STUDIES 63
6.3.2 RISE IN HEALTHCARE EXPENDITURE 63
6.3.3 USE OF ARTIFICIAL INTELLIGENCE IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 64
6.4 CHALLENGES 64
6.4.1 BIOLOGICS NEED SPECIALIST TESTING SERVICES 64
6.4.2 STRINGENT REGULATIONS 65
7 IMPACT OF COVID-19 ON ASIA PACIFIC MEDICINAL CHEMISTRY IN DRUG DISCOVERY MARKET 66
7.1 IMPACT ON PRICE 66
7.2 IMPACT ON DEMAND 66
7.3 IMPACT ON SUPPLY CHAIN 67
7.4 STRATEGIC DECISIONS BY MANUFACTURERS 67
7.5 CONCLUSION 68
8 ASIA PACIFIC MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS 69
8.1 OVERVIEW 70
8.2 TARGET SELECTION 73
8.3 TARGET VALIDATION 73
8.4 HIT-TO-LEAD IDENTIFICATION 74
8.5 LEAD OPTIMIZATION 75
8.6 CANDIDATE VALIDATION 76
9 ASIA PACIFIC MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN 77
9.1 OVERVIEW 78
9.2 FRAGMENT-BASED VARIATION 81
9.3 STRUCTURE BASED DRUG DESIGN 81
9.4 DIVERSITY ORIENTED SYNTHESIS 82
9.5 CHEMOGENOMICS 83
9.6 NATURAL PRODUCTS 84
9.7 OTHERS 85
10 ASIA PACIFIC MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE 86
10.1 OVERVIEW 87
10.2 SMALL MOLECULES 90
10.3 BIOLOGICS 91
11 ASIA PACIFIC MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 92
11.1 OVERVIEW 93
11.2 ONCOLOGY 96
11.3 NEUROLOGY 96
11.4 INFECTIOUS AND IMMUNE SYSTEM DISEASES 97
11.5 CARDIOVASCULAR DISEASES 98
11.6 DIGESTIVE SYSTEM DISEASES 99
11.7 OTHERS 100
12 ASIA PACIFIC MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER 101
12.1 OVERVIEW 102
12.2 CONTRACT RESEARCH ORGANIZATION 106
12.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 106
12.4 ACADEMIC AND RESEARCH INSTITUTES 107
12.5 OTHERS 108
13 ASIA PACIFIC MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY REGION 109
13.1 ASIA-PACIFIC 110
13.1.1 CHINA 117
13.1.2 JAPAN 119
13.1.3 INDIA 121
13.1.4 SOUTH KOREA 123
13.1.5 AUSTRALIA 125
13.1.6 SINGAPORE 127
13.1.7 THAILAND 129
13.1.8 PHILIPPINES 131
13.1.9 MALAYSIA 133
13.1.10 INDONESIA 135
13.1.11 VIETNAM 137
13.1.12 REST OF ASIA-PACIFIC 139
14 ASIA PACIFIC MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: COMPANY LANDSCAPE 140
14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 140
15 SWOT ANALYSIS 141
16 COMPANY PROFILE 142
16.1 EUROFINS SCIENTIFIC 142
16.1.1 COMPANY SNAPSHOT 142
16.1.2 REVENUE ANALYSIS 143
16.1.3 COMPANY SHARE ANALYSIS 143
16.1.4 SERVICE PORTFOLIO 143
16.1.5 RECENT DEVELOPMENT 144
16.2 LABCORP DRUG DEVELOPMENT 145
16.2.1 COMPANY SNAPSHOT 145
16.2.2 REVENUE ANALYSIS 146
16.2.3 COMPANY SHARE ANALYSIS 146
16.2.4 SERVICE PORTFOLIO 147
16.2.5 RECENT DEVELOPMENT 147
16.3 CHARLES RIVER 148
16.3.1 COMPANY SNAPSHOT 148
16.3.2 REVENUE ANALYSIS 148
16.3.3 COMPANY SHARE ANALYSIS 149
16.3.4 SERVICE PORTFOLIO 149
16.3.5 RECENT DEVELOPMENTS 149
16.4 WUXI APPTEC 150
16.4.1 COMPANY SNAPSHOT 150
16.4.2 REVENUE ANALYSIS 150
16.4.3 COMPANY SHARE ANALYSIS 151
16.4.4 SERVICE PORTFOLIO 151
16.4.5 RECENT DEVELOPMENTS 151
16.5 EVOTEC SE 152
16.5.1 COMPANY SNAPSHOT 152
16.5.2 REVENUE ANALYSIS 152
16.5.3 COMPANY SHARE ANALYSIS 153
16.5.4 SERVICE PORTFOLIO 153
16.5.5 RECENT DEVELOPMENTS 153

16.6 PIRAMAL PHARMA SOLUTIONS 154
16.6.1 COMPANY SNAPSHOT 154
16.6.2 SERVICE PORTFOLIO 154
16.6.3 RECENT DEVELOPMENTS 154
16.7 THERMO FISHER SCIENTIFIC INC. 155
16.7.1 COMPANY SNAPSHOT 155
16.7.2 REVENUE ANALYSIS 155
16.7.3 SERVICE PORTFOLIO 156
16.7.4 RECENT DEVELOPMENT 156
16.7.4.1 ACQUISITION 156
16.8 AURIGENE PHARMACEUTICAL SERVICES (A SUBSIDIARY OF DR. REDDY'S LABORATORIES) 157
16.8.1 COMPANY SNAPSHOT 157
16.8.2 REVENUE ANALYSIS 157
16.8.3 SERVICE PORTFOLIO 158
16.8.4 RECENT DEVELOPMENT 158
16.9 AURELIA BIOSCIENCES 159
16.9.1 COMPANY SNAPSHOT 159
16.9.2 SERVICE PORTFOLIO 159
16.9.3 RECENT DEVELOPMENTS 159
16.10 BIOBLOCKS INC 160
16.10.1 COMPANY SNAPSHOT 160
16.10.2 SERVICE PORTFOLIO 160
16.10.3 RECENT DEVELOPMENT 160
16.11 CERTARA INC 161
16.11.1 COMPANY SNAPSHOT 161
16.11.2 REVENUE ANALYSIS 161
16.11.3 SERVICE PORTFOLIO 162
16.11.4 RECENT DEVELOPMENTS 162
16.12 DOMAINEX 163
16.12.1 COMPANY SNAPSHOT 163
16.12.2 SERVICE PORTFOLIO 163
16.12.3 RECENT DEVELOPMENT 163
16.13 DRUG DISCOVERY ALLIANCES 164
16.13.1 COMPANY SNAPSHOT 164
16.13.2 SERVICE PORTFOLIO 164
16.13.3 RECENT DEVELOPMENT 164
16.14 GENSCRIPT BIOTECH 165
16.14.1 COMPANY SNAPSHOT 165
16.14.2 REVENUE ANALYSIS 165
16.14.3 SERVICE PORTFOLIO 166
16.14.4 RECENT DEVELOPMENT 166
16.15 JUBILANT BIOSYS 167
16.15.1 COMPANY SNAPSHOT 167
16.15.2 SERVICE PORTFOLIO 167
16.15.3 RECENT DEVELOPMENTS 167
16.16 NANOSYN 169
16.16.1 COMPANY SNAPSHOT 169
16.16.2 PRODUCT PORTFOLIO 169
16.16.3 RECENT DEVELOPMENT 169
16.17 NEREID THERAPEUTICS 170
16.17.1 COMPANY SNAPSHOT 170
16.17.2 SERVICE PORTFOLIO 170
16.17.3 RECENT DEVELOPMENT 170
16.18 PFIZER INC. 171
16.18.1 COMPANY SNAPSHOT 171
16.18.2 REVENUE ANALYSIS 171
16.18.3 SERVICE PORTFOLIO 172
16.18.4 RECENT DEVELOPMENTS 172
16.19 SELVITA 173
16.19.1 COMPANY SNAPSHOT 173
16.19.2 REVENUE ANALYSIS 173
16.19.3 SERVICE PORTFOLIO 174
16.19.4 RECENT DEVELOPMENTS 174
16.19.4.1 ACQUISITION 174
16.20 SPECTRIS PLC 175
16.20.1 COMPANY SNAPSHOT 175
16.20.2 REVENUE ANALYSIS 175
16.20.3 SERVICE PORTFOLIO 176
16.20.4 RECENT DEVELOPMENT 176
16.21 SYGNATURE DISCOVERY 177
16.21.1 COMPANY SNAPSHOT 177
16.21.2 SERVICE PORTFOLIO 177
16.21.3 RECENT DEVELOPMENTS 177
16.22 TAROS CHEMICAL GMBH 178
16.22.1 COMPANY SNAPSHOT 178
16.22.2 SERVICE PORTFOLIO 178
16.22.3 RECENT DEVELOPMENT 178
17 QUESTIONNAIRE 179
18 RELATED REPORTS 182